Aeterna Zentaris to Discontinue Phase 3 Trial in Multiple Myeloma with Perifosine Following Data Safety Monitoring Board

    Aeterna Zentaris to Discontinue Phase 3 Trial in Multiple Myeloma with
       Perifosine Following Data Safety Monitoring Board Recommendation

PR Newswire

QUEBEC CITY, March 11, 2013

QUEBEC CITY, March 11, 2013 /PRNewswire/ - Aeterna Zentaris Inc.
(NASDAQ:AEZS) (TSX:AEZ) (the"Company") today announced that an independent
Data Safety Monitoring Board ("DSMB") has recommended discontinuing the
ongoing Phase 3 study comparing the efficacy and safety of perifosine to
placebo when combined with bortezomib (Velcade^®) and dexamethasone in
patients with relapsed or relapsed/refractory multiple myeloma. Based on the
outcome of its pre-planned interim analysis of efficacy and safety, the DSMB
recommended that patient enrollment be stopped and the study discontinued. The
DSMB reported that it was highly unlikely the study would achieve a
significant difference in its primary endpoint, progression free survival; no
safety concerns were raised.

Juergen Engel, PhD, Aeterna Zentaris President and CEO stated, "We are
obviously disappointed with the outcome of the interim analysis as reported to
us by the DSMB, both from a patient and Company perspective. However, we
remain focused on other significant opportunities such as our Phase 3 trial in
endometrial cancer and Phase 2 trials in breast, prostate and bladder cancer
with AEZS-108, our NDA filing for AEZS-130 as an oral diagnostic test for
growth hormone deficiency in adults, as well as our earlier-stage oncology
compound, AEZS-120."

About Aeterna Zentaris

Aeterna Zentaris is an oncology and endocrinology drug development company
currently investigating treatments for various unmet medical needs. The
Company's pipeline encompasses compounds at all stages of development, from
drug discovery through to marketed products. For more information please visit

Forward-Looking Statements
This press release contains forward-looking statements made pursuant to the
safe harbour provisions of the U.S. Securities Litigation Reform Act of 1995.
Forward-looking statements involve known and unknown risks and uncertainties
that could cause the Company's actual results to differ materially from those
in the forward-looking statements. Such risks and uncertainties include, among
others, the availability of funds and resources to pursue R&D projects, the
successful and timely completion of clinical studies, the risk that safety and
efficacy data from any of our Phase 3 trials may not coincide with the data
analyses from previously reported Phase 1 and/or Phase 2 clinical trials, the
ability of the Company to take advantage of business opportunities in the
pharmaceutical industry, uncertainties related to the regulatory process and
general changes in economic conditions. Investors should consult the Company's
quarterly and annual filings with the Canadian and U.S. securities commissions
for additional information on risks and uncertainties relating to
forward-looking statements. Investors are cautioned not to rely on these
forward-looking statements. The Company does not undertake to update these
forward-looking statements. We disclaim any obligation to update any such
factors or to publicly announce the result of any revisions to any of the
forward-looking statements contained herein to reflect future results, events
or developments, unless required to do so by a governmental authority or by
applicable law.



Investor Relations
Ginette Beaudet Vallières
Investor Relations Coordinator
(418) 652-8525 ext. 265

Media Relations
Paul Burroughs
Director of Communications
(418) 652-8525 ext. 406
Press spacebar to pause and continue. Press esc to stop.